Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Humanized anti-novel coronavirus neutralizing antibody nCoV-163 and application thereof

An antibody and neutralization technology, applied in the direction of antiviral agents, antiviral immunoglobulins, applications, etc., can solve the problems of not improving the treatment process of patients and not significantly reducing the mortality rate of the new coronavirus, and achieving the effect of high antigen affinity

Active Publication Date: 2021-02-09
中国疾病预防控制中心病毒病预防控制所
View PDF3 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Although multiple drugs such as remdesivir, hydroxychloroquine, lopinavir, and interferon β1a have been proven to be effective against the new crown in vitro, according to the latest WHO research, none of these drugs can significantly reduce the mortality rate of the new coronavirus, nor have they improved patient's course of treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Humanized anti-novel coronavirus neutralizing antibody nCoV-163 and application thereof
  • Humanized anti-novel coronavirus neutralizing antibody nCoV-163 and application thereof
  • Humanized anti-novel coronavirus neutralizing antibody nCoV-163 and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1 Preparation and function of human-derived anti-new coronavirus neutralizing antibody nCoV-163

[0030] 1. Materials

[0031] 1. Samples and carriers: New coronavirus antibody-positive serum and lymphocytes: provided by Wuhan CDC and Shandong CDC. The strain XLI-Blue was purchased from Stratagene Corporation of the United States, and the antibody library construction vector pComb3H (40kb) was donated by the Scripps Research Institute of the United States.

[0032] 2. Antigen: 2019-nCoV RBD protein and S1 protein were provided by Hualan Bioengineering Co., Ltd., 2019-nCoV S protein trimer was provided by Jiangsu Dongkang Biomedical Technology Co., Ltd. RBD protein expression plasmid and S protein full-length Expression plasmids (see Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, DongY, Yang Y, Chen Z, Guo Y, Zhang J, Li Y, Song X, Chen Y ,Xia L,Fu L,Hou L,Xu J,Yu C,Li J,Zhou Q,Chen W.Aneutralizing human antibody binds to the N-terminal domain ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a humanized anti-novel coronavirus neutralizing antibody nCoV-163 and application thereof. According to the humanized anti-novel coronavirus neutralizing antibody nCoV-163 andthe application thereof, the humanized neutralizing antibody nCoV-163 specifically aiming at a novel coronavirus surface antigen is successfully obtained by utilizing a phage antibody library technology, the antibody nCoV-163 is provided with a neutralizing function of preventing novel coronavirus from infecting sensitive cells in vitro and is high in antigen affinity, and the antibody is expectedto be prepared into specific antibody drugs for preventing and treating novel coronavirus pneumonia clinically.

Description

technical field [0001] The present invention relates to the field of biotechnology, in particular to human-derived anti-new coronavirus neutralizing antibody nCoV-163 and its application. Background technique [0002] The novel coronavirus SARS-CoV-2 is a new virus discovered in 2019 that can cause viral pneumonia, or lung infection, in humans. The coronavirus genome sequentially encodes the spike protein, envelope protein, membrane protein and nucleocapsid protein. Among them, the spike protein (Spike) is the most important surface membrane protein of coronavirus, which contains two subunits S1 and S2, of which S1 mainly contains the receptor binding domain (RBD), which is responsible for recognizing the receptors of cells. The SARS-CoV-2 spike protein interacts with human angiotensin-converting enzyme 2 (ACE2) to infect human respiratory epithelial cells. [0003] Although multiple drugs such as remdesivir, hydroxychloroquine, lopinavir, and interferon β1a have been prov...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/10C12N15/13A61K39/42A61P31/14
CPCC07K16/10A61P31/14A61K2039/505C07K2317/565
Inventor 梁米芳孙丽娜曲圆圆殷强玲李德新王世文李川芜为李建东李阿茜黄晓霞
Owner 中国疾病预防控制中心病毒病预防控制所
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com